Kedudukan dalam Saham
#28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Harga Saham
$0.07339369
Disegerakkan terakhir: 2026-08-18
Perubahan (1 tahun)
-9.55%
Perdagangan Resverlogix Corp. (RVX)
Harga RVX dengan permodalan pasaran b
Modal pasaran bagi Resverlogix Corp.(RVX)
Modal Pasaran: $25.24M
Sehingga August 2026, Resverlogix Corp. mempunyai modal pasaran sebanyak $25.24M. Ini menjadikan Resverlogix Corp. syarikat ke-28673rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Resverlogix Corp. dari 2004 hingga 2026
RVX berbanding dengan 5 teratas yang paling popular stocks
| Harga RVX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.301T
|
+20,999,338.36%
|
|
|
|
|
$4.634T
|
+18,357,012.00%
|
|
|
|
|
$4.143T
|
+16,412,357.35%
|
|
|
|
|
$3.589T
|
+14,219,233.93%
|
|
|
|
|
$2.857T
|
+11,317,728.88%
|
